Evidence map›Paper›PMID 38633777›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder.

Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, Marina Belenky, Vasant R Marur, A John Rush, W Edward Craighead, Helen S Mayberg, Boadie W Dunlop, Bruce S Kristal and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Sudeepa BhattacharyyaDepartment of Biological Sciences, Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR, United States.
Siamak MahmoudianDehkordiDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, United States.
Matthew J SniatynskiDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA and Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Marina BelenkyDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA and Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Vasant R MarurDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA and Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
A John RushDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, United States.
W Edward CraigheadDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States.
Helen S MaybergDepartment of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, United States.
Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States.
Bruce S KristalDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA and Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Rima Kaddurah-DaoukDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, United States.
Mood Disorder Precision Medicine Consortium
Brigham and Women's Hospital · USDuke University · USEmory University · USArkansas State University · USIcahn School of Medicine at Mount Sinai · USNational University of Singapore · SG

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 1985 to 2007
$21.3M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Special Scientific Procedures: Statistical Modeling CoreP50MH077083 · NIMH · EMORY UNIVERSITY · PI MAYBERG, HELEN S · 2006 to 2010
$9.3M
Predictors of Treatment Response Relapse and Recurrence in Major DepressionR01MH080880 · NIMH · EMORY UNIVERSITY · PI CRAIGHEAD, W. EDWARD · 2008 to 2012
$6.6M
Metabolic Networks and Pathways in Alzheimer's DiseaseR01AG046171 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F · 2014 to 2017
$4.4M
Metabolomic Signatures Predictive of Outcomes to Treatments for Major DepressionR01MH108348 · NIMH · DUKE UNIVERSITY · PI DUNLOP, BOADIE W, KADDURAH-DAOUK, RIMA F · 2016 to 2019
$2.7M
NCATS NIH HHS UL1 TR002378NCRR NIH HHS M01 RR000039NCRR NIH HHS UL1 RR025008NIA NIH HHS R01 AG046171NIA NIH HHS U01 AG061359NIMH NIH HHS P50 MH077083NIMH NIH HHS R01 MH080880NIMH NIH HHS R01 MH108348
6 · The paper itself

Abstract

Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive Behavior Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways. Changes in metabolite concentrations related to each treatment arm were identified and compared to define metabolic signatures of exposure. In addition, association between metabolites and depressive symptom severity (assessed with the 17-item Hamilton Rating Scale for Depression [HRSD

Identifiers

PMID38633777
PMCPMC11023644
OpenAlexW4393900135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.